L
L. Fouillard
Researcher at University of Paris
Publications - 41
Citations - 2144
L. Fouillard is an academic researcher from University of Paris. The author has contributed to research in topics: Bone marrow & Transplantation. The author has an hindex of 23, co-authored 41 publications receiving 2063 citations. Previous affiliations of L. Fouillard include Pierre-and-Marie-Curie University.
Papers
More filters
Journal ArticleDOI
Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.
A Fassas,Jakob Passweg,Achilles Anagnostopoulos,Aristidis Kazis,Tomas Kozak,Eva Havrdova,Enric Carreras,Francesc Graus,Ashwin Kashyap,Harry Openshaw,M. Schipperus,Eric Deconinck,G. L. Mancardi,Alberto M. Marmont,J. Hansz,Marco Rabusin,F. J. Zuazu Nagore,J. Besalduch,T. Dentamaro,L. Fouillard,Bernd Hertenstein,G. La Nasa,Marco Musso,Federico Papineschi,J. M. Rowe,Riccardo Saccardi,Andreas J. Steck,Ludwig Kappos,Alois Gratwohl,Alan Tyndall,Marrow Transplantation +30 more
TL;DR: Autologous HSCT suggest positive early results in the management of progressive MS and is feasible and is being utilised in the planning of future trials to reduce transplant related mortality.
Journal ArticleDOI
Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells.
Aisha Nasef,Alain Chapel,Christelle Mazurier,Sandrine Bouchet,Manuel Rodríguez López,Noelle Mathieu,Luc Sensebé,Yizhuo Zhang,Norbert Claude Gorin,Dominique Thierry,L. Fouillard,L. Fouillard +11 more
TL;DR: MSC appear to induce T-cell tolerance by two distinct mechanisms, the first of which does not require cell contact, induces expression of the tolerogenic genes IDO, LIF, and HLA-G, and the second mechanism, which is contact dependent, modulates IL-10 and TGF-beta gene expression.
Journal ArticleDOI
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database.
Riccardo Saccardi,Tomas Kozak,Chiara Bocelli-Tyndall,A Fassas,Aristidis Kazis,Eva Havrdova,Enric Carreras,Albert Saiz,Bob Löwenberg,P Aw te Boekhorst,Francesca Gualandi,Harry Openshaw,G Longo,F Pagliai,Luca Massacesi,E Deconink,J Ouyang,F Jz Nagore,Juan Besalduch,I. Lisukov,A Bonini,Elisa Merelli,Shimon Slavin,Alois Gratwohl,Jakob Passweg,Alan Tyndall,Andreas J. Steck,M Andolina,Marco Capobianco,J Ld Martin,Alessandra Lugaresi,Giuseppe Meucci,Ricardo Saez,Richard E. Clark,Mario Fernandez,L. Fouillard,B. Herstenstein,Vladimir Koza,Eleonora Cocco,H Baurmann,G. L. Mancardi +40 more
TL;DR: HSCT was shown as a promising procedure to slow down progression in a subset of patients affected by severe, progressive MS; the safety and feasibility of the procedure can be significantly improved by appropriate patient selection and choice of transplant regimen.
Journal ArticleDOI
Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma.
L. Fouillard,Morad Bensidhoum,Bories D,Bonte H,Manuel Lopez,Moseley Am,Andrea L. Smith,S Lesage,Beaujean F,Dominique Thierry,Gourmelon P,Najman A,Norbert-Claude Gorin +12 more
TL;DR: Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma.
Journal ArticleDOI
Autologous haematopoietic stem cell transplants for autoimmune disease - feasibility and transplant-related mortality
A Tyndall,Athanasios Fassas,Jakob Passweg,C Ruiz de Elvira,Michel Attal,Peter Brooks,Christopher M. Black,P Durez,Jürgen Finke,S.J. Forman,L. Fouillard,Daniel E. Furst,Jonathan A. Holmes,David Joske,Jean-Pierre Jouet,I. Kotter,Franco Locatelli,H. G. Prentice,Alberto M. Marmont,Peter A. McSweeney,Marco Musso,Hans-Hartmut Peter,John A. Snowden,Keith M. Sullivan,André Tichelli,J Vavriec,NM Wulffraat,N. Schmitz,Alois Gratwohl +28 more
TL;DR: Preliminary data are promising, and randomised trials comparing autologous stem cell transplants to conventional therapy are warranted, as transplant-related mortality is comparable to results in patients with non-Hodgkin’s lymphoma in responsive relapse.